AbCellera Biologics Inc. (ABCL)

AbCellera Biologics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	83.16	156.33	133.32	386.54	476.14	594.12
Short-Term Investments	412.51	469.29	627.27	499.95	246.84	-
Cash & Short-Term Investments	495.67	625.61	760.59	886.49	722.98	594.12
Cash Growth	-22.93%	-17.75%	-14.20%	22.62%	21.69%	7765.96%
Accounts Receivable	41.46	33.62	30.59	38.59	160.58	213.24
Other Receivables	46.66	26.53	33.79	64.82	14.28	0.49
Receivables	159.36	92.13	64.38	103.41	174.86	213.73
Inventory	-	-	-	1.53	1.67	1.41
Prepaid Expenses	15.11	8.63	22.02	9.06	5.29	4.07
Restricted Cash	25	25	25	25	25	-
Total Current Assets	695.14	751.37	871.99	1,025	929.8	813.33
Property, Plant & Equipment	427.36	340.43	287.7	217.26	111.62	17.92
Long-Term Investments	93.3	82.3	65.94	34.42	32.31	20.03
Goodwill	47.81	47.81	47.81	47.81	47.81	31.5
Other Intangible Assets	39.32	42.11	120.43	131.5	148.39	115.15
Long-Term Deferred Tax Assets	-	-	-	-	-	5.9
Other Long-Term Assets	53.07	66.94	80.34	40.83	30.64	1.71
Total Assets	1,356	1,361	1,488	1,541	1,319	1,006
Accounts Payable	31.77	34.35	28.6	14.83	14.92	7.32
Accrued Expenses	7.23	8.38	7.71	25.8	26.54	29.13
Current Portion of Leases	5.17	4.62	6.16	5.58	3.65	0.68
Current Income Taxes Payable	-	-	-	-	35.68	36.15
Current Unearned Revenue	24.63	21.18	26.07	27.9	12.01	7.53
Other Current Liabilities	-	8.09	50.48	44.21	27.87	22.68
Total Current Liabilities	68.8	76.61	119.01	118.32	120.68	103.49
Long-Term Leases	137.05	60.74	71.22	76.68	36.41	3.72
Long-Term Unearned Revenue	174.97	155.59	104.11	60.32	60.76	25.89
Long-Term Deferred Tax Liabilities	9.74	10.05	30.61	33.18	37.37	26.16
Other Long-Term Liabilities	1.39	1.47	10.82	19.14	37.62	15.77
Total Liabilities	391.95	304.47	335.78	307.63	292.84	175.03
Common Stock	794.47	777.17	753.2	734.37	722.43	710.39
Additional Paid-In Capital	192.8	166.36	121.05	74.12	35.36	5.92
Retained Earnings	-20.54	116.93	279.79	426.19	267.67	114.2
Comprehensive Income & Other	-2.7	-4.38	-1.72	-1.39	0.28	-
Total Common Equity	964.04	1,056	1,152	1,233	1,026	830.51
Shareholders' Equity	964.04	1,056	1,152	1,233	1,026	830.51
Total Liabilities & Equity	1,356	1,361	1,488	1,541	1,319	1,006
Total Debt	142.22	65.36	77.38	82.26	40.07	4.39
Net Cash (Debt)	353.45	560.25	683.21	804.23	682.91	589.73
Net Cash Growth	-38.18%	-18.00%	-15.05%	17.76%	15.80%	88982.48%
Net Cash Per Share	1.19	1.90	2.36	2.55	2.15	2.24
Filing Date Shares Outstanding	299.34	297.99	292.78	287.69	283.92	269.5
Total Common Shares Outstanding	295.76	295.76	290.82	286.85	283.26	269.5
Working Capital	626.34	674.76	752.97	907.17	809.12	709.84
Book Value Per Share	3.26	3.57	3.96	4.30	3.62	3.08
Tangible Book Value	876.91	966.17	984.09	1,054	829.54	683.86
Tangible Book Value Per Share	2.96	3.27	3.38	3.67	2.93	2.54
Land	53.41	53.41	53.41	53.41	33.04	-
Buildings	53.11	52.91	43.95	11.36	1.21	-
Machinery	97.16	84.29	73.87	49.56	26.65	15.87
Leasehold Improvements	138.4	122.89	73.94	40.57	22.75	3.71

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q